# A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

> **NCT06446128** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Cell Therapy Group Co.,Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma, B-cell

## Interventions

- **BIOLOGICAL:** CD19/CD20/BCMA CAR T cells

## Key facts

- **NCT ID:** NCT06446128
- **Lead sponsor:** Shanghai Cell Therapy Group Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446128, "A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06446128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*